↑ トップへ　← 戻る

Target Gene/Pathway（薬物標的遺伝子／パスウェイリスト）💬 Info on mouse-over

e.g. Sirolimus, アダリムマブ, MAP2K

ABCDEFGH I JKLMNOPQRSTUVWXYZother

148 / 286 pathways

No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related		 KEGG GENES KEGG DRUG DrugBank 指定難病告示番号
1 Acute myeloid leukemia 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
2 Acute myeloid leukemia 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
3 Adherens junction 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
4 Adipocytokine signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
5 Adipocytokine signaling pathway 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
6 Adipocytokine signaling pathway 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
7 Adipocytokine signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
8 African trypanosomiasis 💬
 1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
9 African trypanosomiasis 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
10 African trypanosomiasis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
11 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
12 AGE-RAGE signaling pathway in diabetic complications 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
13 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
14 AGE-RAGE signaling pathway in diabetic complications 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
15 Alanine, aspartate and glutamate metabolism 💬
 4件: ABAT, ALDH5A1, GAD1, GAD2 💬 D00399 💬 Valproic acid 16件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 222, 233, 256, 331 💬
16 Aldosterone synthesis and secretion 💬
 3件: CACNA1G, CACNA1H, CACNA1I 💬 D00399 💬 Valproic acid 16件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 222, 233, 256, 331 💬
17 Allograft rejection 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
18 Allograft rejection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
19 Alzheimer disease 💬
 1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
20 Alzheimer disease 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
21 Alzheimer disease 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
22 Alzheimer disease 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
23 Alzheimer disease 💬
 1件: PSMB5 💬 D03150 💬 Bortezomib 15件: 11, 13, 26, 28, 46, 49, 51, 61, 63, 66, 228, 256, 283, 288, 331 💬
24 Alzheimer disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
25 Alzheimer disease 💬
 9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D02197 💬 Vincristine 3件: 26, 34, 331 💬
26 Alzheimer disease 💬
 9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D08679 💬 Vincristine 3件: 26, 34, 331 💬
27 Amoebiasis 💬
 1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
28 Amoebiasis 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
29 Amoebiasis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
30 AMPK signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
31 AMPK signaling pathway 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
32 Amyotrophic lateral sclerosis 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
33 Amyotrophic lateral sclerosis 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
34 Amyotrophic lateral sclerosis 💬
 1件: PSMB5 💬 D03150 💬 Bortezomib 15件: 11, 13, 26, 28, 46, 49, 51, 61, 63, 66, 228, 256, 283, 288, 331 💬
35 Amyotrophic lateral sclerosis 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
36 Amyotrophic lateral sclerosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
37 Amyotrophic lateral sclerosis 💬
 9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D02197 💬 Vincristine 3件: 26, 34, 331 💬
38 Amyotrophic lateral sclerosis 💬
 9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D08679 💬 Vincristine 3件: 26, 34, 331 💬
39 Antifolate resistance 💬
 2件: DHFR, DHFR2 💬 D00142 💬 Methotrexate 35件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 271, 284, 285, 326, 331 💬
40 Antifolate resistance 💬
 2件: DHFR, DHFR2 💬 D02115 💬 Methotrexate 35件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 271, 284, 285, 326, 331 💬
41 Antifolate resistance 💬
 1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
42 Antifolate resistance 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
43 Antifolate resistance 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
44 Antigen processing and presentation 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
45 Antigen processing and presentation 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
46 Apelin signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
47 Apelin signaling pathway 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
48 Apoptosis 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
49 Apoptosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
50 Asthma 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
51 Asthma 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
52 Autophagy - animal 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
53 Autophagy - animal 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
54 Autophagy - other 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
55 Autophagy - other 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
56 beta-Alanine metabolism 💬
 3件: ABAT, GAD1, GAD2 💬 D00399 💬 Valproic acid 16件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 222, 233, 256, 331 💬
57 Biosynthesis of cofactors 💬
 2件: DHFR, DHFR2 💬 D00142 💬 Methotrexate 35件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 271, 284, 285, 326, 331 💬
58 Biosynthesis of cofactors 💬
 2件: DHFR, DHFR2 💬 D02115 💬 Methotrexate 35件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 271, 284, 285, 326, 331 💬
59 Bladder cancer 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
60 Bladder cancer 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
61 Breast cancer 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
62 Breast cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
63 Breast cancer 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
64 Butanoate metabolism 💬
 4件: ABAT, ALDH5A1, GAD1, GAD2 💬 D00399 💬 Valproic acid 16件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 222, 233, 256, 331 💬
65 C-type lectin receptor signaling pathway 💬
 1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
66 C-type lectin receptor signaling pathway 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
67 C-type lectin receptor signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
68 Calcium signaling pathway 💬
 3件: CACNA1G, CACNA1H, CACNA1I 💬 D00399 💬 Valproic acid 16件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 222, 233, 256, 331 💬
69 Calcium signaling pathway 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
70 Calcium signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
71 Cellular senescence 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
72 Cellular senescence 💬
 1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
73 Cellular senescence 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
74 Cellular senescence 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
75 Central carbon metabolism in cancer 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
76 Central carbon metabolism in cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
77 Central carbon metabolism in cancer 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
78 Chagas disease 💬
 1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
79 Chagas disease 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
80 Chagas disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
81 Choline metabolism in cancer 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
82 Choline metabolism in cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
83 Choline metabolism in cancer 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
84 Circadian entrainment 💬
 3件: CACNA1G, CACNA1H, CACNA1I 💬 D00399 💬 Valproic acid 16件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 222, 233, 256, 331 💬
85 Colorectal cancer 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
86 Colorectal cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
87 Colorectal cancer 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
88 Coronavirus disease - COVID-19 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
89 Coronavirus disease - COVID-19 💬
 1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
90 Coronavirus disease - COVID-19 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
91 Coronavirus disease - COVID-19 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 18件:  2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
92 Coronavirus disease - COVID-19 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
93 Cortisol synthesis and secretion 💬
 3件: CACNA1G, CACNA1H, CACNA1I 💬 D00399 💬 Valproic acid 16件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 222, 233, 256, 331 💬
94 Cushing syndrome 💬
 3件: CACNA1G, CACNA1H, CACNA1I 💬 D00399 💬 Valproic acid 16件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 222, 233, 256, 331 💬
95 Cushing syndrome 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
96 Cytokine-cytokine receptor interaction 💬
 1件: CSF3R 💬 D03235 💬 Filgrastim 33件:  2 ,  6 , 11, 13, 16, 25, 26, 28, 34, 35, 36, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
97 Cytokine-cytokine receptor interaction 💬
 1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
98 Cytokine-cytokine receptor interaction 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
99 Cytokine-cytokine receptor interaction 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 18件:  2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
100 Cytokine-cytokine receptor interaction 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
101 Cytosolic DNA-sensing pathway 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
102 Cytosolic DNA-sensing pathway 💬
 1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
103 Diabetic cardiomyopathy 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
104 Diabetic cardiomyopathy 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
105 Dilated cardiomyopathy 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
106 Dilated cardiomyopathy 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
107 EGFR tyrosine kinase inhibitor resistance 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
108 EGFR tyrosine kinase inhibitor resistance 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
109 EGFR tyrosine kinase inhibitor resistance 💬
 1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
110 EGFR tyrosine kinase inhibitor resistance 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 18件:  2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
111 EGFR tyrosine kinase inhibitor resistance 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
112 EGFR tyrosine kinase inhibitor resistance 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
113 EGFR tyrosine kinase inhibitor resistance 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
114 Endocrine resistance 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
115 Endocrine resistance 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
116 Endocrine resistance 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
117 Endocytosis 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
118 Endometrial cancer 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
119 Epithelial cell signaling in Helicobacter pylori infection 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
120 Epstein-Barr virus infection 💬
 1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
121 Epstein-Barr virus infection 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
122 Epstein-Barr virus infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
123 ErbB signaling pathway 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
124 ErbB signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
125 ErbB signaling pathway 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
126 Estrogen signaling pathway 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
127 Fc epsilon RI signaling pathway 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
128 Fc epsilon RI signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
129 Fluid shear stress and atherosclerosis 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
130 Fluid shear stress and atherosclerosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
131 Fluid shear stress and atherosclerosis 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
132 Focal adhesion 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
133 Focal adhesion 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
134 Folate biosynthesis 💬
 2件: DHFR, DHFR2 💬 D00142 💬 Methotrexate 35件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 271, 284, 285, 326, 331 💬
135 Folate biosynthesis 💬
 2件: DHFR, DHFR2 💬 D02115 💬 Methotrexate 35件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 271, 284, 285, 326, 331 💬
136 FoxO signaling pathway 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
137 FoxO signaling pathway 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
138 FoxO signaling pathway 💬
 1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
139 GABAergic synapse 💬
 3件: ABAT, GAD1, GAD2 💬 D00399 💬 Valproic acid 16件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 222, 233, 256, 331 💬
140 Gap junction 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
141 Gap junction 💬
 9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D02197 💬 Vincristine 3件: 26, 34, 331 💬
142 Gap junction 💬
 9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D08679 💬 Vincristine 3件: 26, 34, 331 💬
143 Gastric cancer 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
144 Gastric cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
145 Gastric cancer 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
146 Glioma 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
147 Glioma 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
148 Glioma 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
149 GnRH secretion 💬
 3件: CACNA1G, CACNA1H, CACNA1I 💬 D00399 💬 Valproic acid 16件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 222, 233, 256, 331 💬
150 GnRH signaling pathway 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
151 Graft-versus-host disease 💬
 1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
152 Graft-versus-host disease 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
153 Graft-versus-host disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
154 Growth hormone synthesis, secretion and action 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
155 Growth hormone synthesis, secretion and action 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
156 Hematopoietic cell lineage 💬
 1件: CSF3R 💬 D03235 💬 Filgrastim 33件:  2 ,  6 , 11, 13, 16, 25, 26, 28, 34, 35, 36, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
157 Hematopoietic cell lineage 💬
 1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
158 Hematopoietic cell lineage 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
159 Hematopoietic cell lineage 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 18件:  2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
160 Hematopoietic cell lineage 💬
 1件: MS4A1 💬 D02994 💬 Rituximab 47件: 11, 13, 14, 17, 19, 35, 36, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331 💬
161 Hematopoietic cell lineage 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
162 Hepatitis B 💬
 1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
163 Hepatitis B 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
164 Hepatitis B 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
165 Hepatitis C 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
166 Hepatitis C 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
167 Hepatitis C 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
168 Hepatocellular carcinoma 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
169 Hepatocellular carcinoma 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
170 Hepatocellular carcinoma 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
171 Herpes simplex virus 1 infection 💬
 1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
172 Herpes simplex virus 1 infection 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
173 Herpes simplex virus 1 infection 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
174 Herpes simplex virus 1 infection 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
175 Herpes simplex virus 1 infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
176 HIF-1 signaling pathway 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
177 HIF-1 signaling pathway 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
178 HIF-1 signaling pathway 💬
 1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
179 HIF-1 signaling pathway 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 18件:  2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
180 HIF-1 signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
181 HIF-1 signaling pathway 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
182 HIF-1 signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
183 Human cytomegalovirus infection 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
184 Human cytomegalovirus infection 💬
 1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
185 Human cytomegalovirus infection 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
186 Human cytomegalovirus infection 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 18件:  2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
187 Human cytomegalovirus infection 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
188 Human cytomegalovirus infection 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
189 Human cytomegalovirus infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
190 Human cytomegalovirus infection 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
191 Human immunodeficiency virus 1 infection 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
192 Human immunodeficiency virus 1 infection 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
193 Human immunodeficiency virus 1 infection 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
194 Human immunodeficiency virus 1 infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
195 Human papillomavirus infection 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
196 Human papillomavirus infection 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
197 Human papillomavirus infection 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
198 Human papillomavirus infection 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
199 Human papillomavirus infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
200 Human papillomavirus infection 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
201 Human T-cell leukemia virus 1 infection 💬
 1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
202 Human T-cell leukemia virus 1 infection 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
203 Human T-cell leukemia virus 1 infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
204 Huntington disease 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
205 Huntington disease 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
206 Huntington disease 💬
 1件: PSMB5 💬 D03150 💬 Bortezomib 15件: 11, 13, 26, 28, 46, 49, 51, 61, 63, 66, 228, 256, 283, 288, 331 💬
207 Huntington disease 💬
 9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D02197 💬 Vincristine 3件: 26, 34, 331 💬
208 Huntington disease 💬
 9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D08679 💬 Vincristine 3件: 26, 34, 331 💬
209 Hypertrophic cardiomyopathy 💬
 1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
210 Hypertrophic cardiomyopathy 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
211 Hypertrophic cardiomyopathy 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
212 IL-17 signaling pathway 💬
 1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
213 IL-17 signaling pathway 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
214 IL-17 signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
215 Inflammatory bowel disease 💬
 1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
216 Inflammatory bowel disease 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
217 Inflammatory bowel disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
218 Influenza A 💬
 1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
219 Influenza A 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
220 Influenza A 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
221 Insulin resistance 💬
 1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
222 Insulin resistance 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
223 Insulin resistance 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
224 Insulin resistance 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
225 Insulin resistance 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
226 Insulin signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
227 Insulin signaling pathway 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
228 Intestinal immune network for IgA production 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
229 Intestinal immune network for IgA production 💬
 1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
230 JAK-STAT signaling pathway 💬
 1件: CSF3R 💬 D03235 💬 Filgrastim 33件:  2 ,  6 , 11, 13, 16, 25, 26, 28, 34, 35, 36, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
231 JAK-STAT signaling pathway 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
232 JAK-STAT signaling pathway 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
233 JAK-STAT signaling pathway 💬
 1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
234 JAK-STAT signaling pathway 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 18件:  2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
235 JAK-STAT signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
236 JAK-STAT signaling pathway 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
237 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
238 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
239 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
240 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
241 Kaposi sarcoma-associated herpesvirus infection 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
242 Legionellosis 💬
 1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
243 Legionellosis 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
244 Legionellosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
245 Leishmaniasis 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
246 Leishmaniasis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
247 Longevity regulating pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
248 Longevity regulating pathway 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
249 Longevity regulating pathway - multiple species 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
250 Longevity regulating pathway - multiple species 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
251 Malaria 💬
 1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
252 Malaria 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
253 Malaria 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
254 MAPK signaling pathway 💬
 3件: CACNA1G, CACNA1H, CACNA1I 💬 D00399 💬 Valproic acid 16件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 222, 233, 256, 331 💬
255 MAPK signaling pathway 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
256 MAPK signaling pathway 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
257 MAPK signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
258 MAPK signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
259 Measles 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
260 Measles 💬
 1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
261 Melanoma 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
262 Metabolic pathways 💬
 4件: ABAT, ALDH5A1, GAD1, GAD2 💬 D00399 💬 Valproic acid 16件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 222, 233, 256, 331 💬
263 Metabolic pathways 💬
 2件: DHFR, DHFR2 💬 D00142 💬 Methotrexate 35件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 271, 284, 285, 326, 331 💬
264 Metabolic pathways 💬
 2件: DHFR, DHFR2 💬 D02115 💬 Methotrexate 35件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 271, 284, 285, 326, 331 💬
265 MicroRNAs in cancer 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
266 MicroRNAs in cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
267 MicroRNAs in cancer 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
268 MicroRNAs in cancer 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
269 mTOR signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
270 mTOR signaling pathway 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
271 mTOR signaling pathway 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
272 mTOR signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
273 Natural killer cell mediated cytotoxicity 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
274 Natural killer cell mediated cytotoxicity 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
275 Necroptosis 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
276 Necroptosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
277 Neuroactive ligand-receptor interaction 💬
 1件: NR3C1 💬 D00473 💬 Prednisone 47件:  2 ,  6 , 11, 13, 14, 19, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 81, 84, 85, 86, 93, 95, 96, 97, 113, 127, 162, 164, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 💬
278 Neutrophil extracellular trap formation 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
279 Neutrophil extracellular trap formation 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
280 NF-kappa B signaling pathway 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
281 NF-kappa B signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
282 NOD-like receptor signaling pathway 💬
 1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
283 NOD-like receptor signaling pathway 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
284 NOD-like receptor signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
285 Non-alcoholic fatty liver disease 💬
 1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
286 Non-alcoholic fatty liver disease 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
287 Non-alcoholic fatty liver disease 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 18件:  2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
288 Non-alcoholic fatty liver disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
289 Non-small cell lung cancer 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
290 One carbon pool by folate 💬
 2件: DHFR, DHFR2 💬 D00142 💬 Methotrexate 35件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 271, 284, 285, 326, 331 💬
291 One carbon pool by folate 💬
 2件: DHFR, DHFR2 💬 D02115 💬 Methotrexate 35件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 271, 284, 285, 326, 331 💬
292 Osteoclast differentiation 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
293 Osteoclast differentiation 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
294 Oxytocin signaling pathway 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
295 Pancreatic cancer 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
296 Pancreatic cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
297 Pancreatic cancer 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
298 Pancreatic cancer 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
299 Parathyroid hormone synthesis, secretion and action 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
300 Parkinson disease 💬
 1件: PSMB5 💬 D03150 💬 Bortezomib 15件: 11, 13, 26, 28, 46, 49, 51, 61, 63, 66, 228, 256, 283, 288, 331 💬
301 Parkinson disease 💬
 9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D02197 💬 Vincristine 3件: 26, 34, 331 💬
302 Parkinson disease 💬
 9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D08679 💬 Vincristine 3件: 26, 34, 331 💬
303 Pathogenic Escherichia coli infection 💬
 1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
304 Pathogenic Escherichia coli infection 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
305 Pathogenic Escherichia coli infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
306 Pathogenic Escherichia coli infection 💬
 9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D02197 💬 Vincristine 3件: 26, 34, 331 💬
307 Pathogenic Escherichia coli infection 💬
 9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D08679 💬 Vincristine 3件: 26, 34, 331 💬
308 Pathways in cancer 💬
 1件: CSF3R 💬 D03235 💬 Filgrastim 33件:  2 ,  6 , 11, 13, 16, 25, 26, 28, 34, 35, 36, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
309 Pathways in cancer 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
310 Pathways in cancer 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
311 Pathways in cancer 💬
 1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
312 Pathways in cancer 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 18件:  2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
313 Pathways in cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
314 Pathways in cancer 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
315 Pathways in cancer 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
316 Pathways of neurodegeneration - multiple diseases 💬
 1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
317 Pathways of neurodegeneration - multiple diseases 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
318 Pathways of neurodegeneration - multiple diseases 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
319 Pathways of neurodegeneration - multiple diseases 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
320 Pathways of neurodegeneration - multiple diseases 💬
 1件: PSMB5 💬 D03150 💬 Bortezomib 15件: 11, 13, 26, 28, 46, 49, 51, 61, 63, 66, 228, 256, 283, 288, 331 💬
321 Pathways of neurodegeneration - multiple diseases 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
322 Pathways of neurodegeneration - multiple diseases 💬
 9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D02197 💬 Vincristine 3件: 26, 34, 331 💬
323 Pathways of neurodegeneration - multiple diseases 💬
 9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D08679 💬 Vincristine 3件: 26, 34, 331 💬
324 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
325 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
326 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
327 Pertussis 💬
 1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
328 Pertussis 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
329 Pertussis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
330 Phagosome 💬
 9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D02197 💬 Vincristine 3件: 26, 34, 331 💬
331 Phagosome 💬
 9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D08679 💬 Vincristine 3件: 26, 34, 331 💬
332 Phospholipase D signaling pathway 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
333 Phospholipase D signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
334 Phospholipase D signaling pathway 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
335 PI3K-Akt signaling pathway 💬
 1件: CSF3R 💬 D03235 💬 Filgrastim 33件:  2 ,  6 , 11, 13, 16, 25, 26, 28, 34, 35, 36, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
336 PI3K-Akt signaling pathway 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
337 PI3K-Akt signaling pathway 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
338 PI3K-Akt signaling pathway 💬
 1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
339 PI3K-Akt signaling pathway 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 18件:  2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
340 PI3K-Akt signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
341 PI3K-Akt signaling pathway 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
342 PI3K-Akt signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
343 Platinum drug resistance 💬
 2件: TOP2A, TOP2B 💬 D03899 💬 Doxorubicin 4件: 26, 28, 34, 331 💬
344 Platinum drug resistance 💬
 2件: TOP2A, TOP2B 💬 D00125 💬 Etoposide 11件: 11, 13, 14, 26, 28, 34, 60, 65, 85, 164, 331 💬
345 Platinum drug resistance 💬
 2件: TOP2A, TOP2B 💬 D04107 💬 Etoposide 11件: 11, 13, 14, 26, 28, 34, 60, 65, 85, 164, 331 💬
346 Prion disease 💬
 1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
347 Prion disease 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
348 Prion disease 💬
 1件: PSMB5 💬 D03150 💬 Bortezomib 15件: 11, 13, 26, 28, 46, 49, 51, 61, 63, 66, 228, 256, 283, 288, 331 💬
349 Prion disease 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
350 Prion disease 💬
 9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D02197 💬 Vincristine 3件: 26, 34, 331 💬
351 Prion disease 💬
 9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D08679 💬 Vincristine 3件: 26, 34, 331 💬
352 Propanoate metabolism 💬
 1件: ABAT 💬 D00399 💬 Valproic acid 16件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 222, 233, 256, 331 💬
353 Prostate cancer 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
354 Prostate cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
355 Prostate cancer 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
356 Proteasome 💬
 1件: PSMB5 💬 D03150 💬 Bortezomib 15件: 11, 13, 26, 28, 46, 49, 51, 61, 63, 66, 228, 256, 283, 288, 331 💬
357 Proteoglycans in cancer 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
358 Proteoglycans in cancer 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
359 Proteoglycans in cancer 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
360 Proteoglycans in cancer 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
361 Proteoglycans in cancer 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
362 Proteoglycans in cancer 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
363 Rap1 signaling pathway 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
364 Rap1 signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
365 Ras signaling pathway 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
366 Ras signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
367 Regulation of actin cytoskeleton 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
368 Relaxin signaling pathway 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
369 Relaxin signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
370 Renal cell carcinoma 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
371 Rheumatoid arthritis 💬
 1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
372 Rheumatoid arthritis 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
373 Rheumatoid arthritis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
374 Rheumatoid arthritis 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
375 RIG-I-like receptor signaling pathway 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
376 RIG-I-like receptor signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
377 Salmonella infection 💬
 1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
378 Salmonella infection 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
379 Salmonella infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
380 Salmonella infection 💬
 9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D02197 💬 Vincristine 3件: 26, 34, 331 💬
381 Salmonella infection 💬
 9件: TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 D08679 💬 Vincristine 3件: 26, 34, 331 💬
382 Shigellosis 💬
 1件: EGFR 💬 D03455 💬 Cetuximab 5件: 34, 51, 86, 89, 331 💬
383 Shigellosis 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
384 Shigellosis 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
385 Shigellosis 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
386 Shigellosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
387 Sphingolipid signaling pathway 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
388 Sphingolipid signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
389 Spinocerebellar ataxia 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
390 Spinocerebellar ataxia 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
391 Spinocerebellar ataxia 💬
 1件: PSMB5 💬 D03150 💬 Bortezomib 15件: 11, 13, 26, 28, 46, 49, 51, 61, 63, 66, 228, 256, 283, 288, 331 💬
392 Systemic lupus erythematosus 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
393 Systemic lupus erythematosus 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
394 T cell receptor signaling pathway 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
395 T cell receptor signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
396 Taurine and hypotaurine metabolism 💬
 2件: GAD1, GAD2 💬 D00399 💬 Valproic acid 16件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 222, 233, 256, 331 💬
397 TGF-beta signaling pathway 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
398 TGF-beta signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
399 Th17 cell differentiation 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
400 Th17 cell differentiation 💬
 1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
401 Th17 cell differentiation 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 18件:  2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
402 Th17 cell differentiation 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
403 Th17 cell differentiation 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
404 Thermogenesis 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
405 Thermogenesis 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
406 Thyroid hormone signaling pathway 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
407 Thyroid hormone signaling pathway 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
408 TNF signaling pathway 💬
 1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
409 TNF signaling pathway 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
410 TNF signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
411 Toll-like receptor signaling pathway 💬
 1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
412 Toll-like receptor signaling pathway 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
413 Toll-like receptor signaling pathway 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
414 Toxoplasmosis 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
415 Toxoplasmosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
416 Transcriptional misregulation in cancer 💬
 1件: IL6 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
417 Transcriptional misregulation in cancer 💬
 1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
418 Tuberculosis 💬
 1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
419 Tuberculosis 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
420 Tuberculosis 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
421 Type I diabetes mellitus 💬
 2件: GAD1, GAD2 💬 D00399 💬 Valproic acid 16件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 222, 233, 256, 331 💬
422 Type I diabetes mellitus 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
423 Type I diabetes mellitus 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
424 Type II diabetes mellitus 💬
 1件: CACNA1G 💬 D00399 💬 Valproic acid 16件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 222, 233, 256, 331 💬
425 Type II diabetes mellitus 💬
 1件: MTOR 💬 D00753 💬 Sirolimus 40件:  2 ,  6 , 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331 💬
426 Type II diabetes mellitus 💬
 1件: MTOR 💬 D06068 💬 Temsirolimus 4件: 13, 34, 89, 331 💬
427 Type II diabetes mellitus 💬
 1件: TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
428 Type II diabetes mellitus 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
429 Valine, leucine and isoleucine degradation 💬
 1件: ABAT 💬 D00399 💬 Valproic acid 16件:  2 ,  3 ,  5 ,  6 , 13, 26, 34, 65, 85, 89, 90, 102, 222, 233, 256, 331 💬
430 VEGF signaling pathway 💬
 1件: VEGFA 💬 D06409 💬 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331 💬
431 Viral protein interaction with cytokine and cytokine receptor 💬
 1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
432 Viral protein interaction with cytokine and cytokine receptor 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
433 Viral protein interaction with cytokine and cytokine receptor 💬
 1件: IL6R 💬 D02596 💬 Tocilizumab 18件:  2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
434 Viral protein interaction with cytokine and cytokine receptor 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
435 Yersinia infection 💬
 1件: IL6 💬 D09669 💬 Siltuximab 2件: 28, 331 💬
436 Yersinia infection 💬
 2件: IL6, TNF 💬 D08976 💬 Pomalidomide 6件: 28, 34, 51, 85, 227, 331 💬
437 Yersinia infection 💬
 1件: TNF 💬 D00754 💬 Thalidomide 20件:  2 , 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬

先頭へ